Research progress on mesenchymal stem cell products and their exosomes in the treatment of inflammatory bowel disease

YANG Jingwen; CHEN Qian; SHAN Yunlong; LIU Jiali; WEI Ning; WANG Jing; WANG Guangji; ZHOU Fang

doi:10.11665/j.issn.1000-5048.2023113001

Journal of China Pharmaceutical University > 2024 > 55(1): 103-114. > DOI: 10.11665/j.issn.1000-5048.2023113001

YANG Jingwen, CHEN Qian, SHAN Yunlong, et al. Research progress on mesenchymal stem cell products and their exosomes in the treatment of inflammatory bowel disease[J]. J China Pharm Univ, 2024, 55(1): 103 − 114. DOI: 10.11665/j.issn.1000-5048.2023113001

Citation:

PDF (3828 KB)

Research progress on mesenchymal stem cell products and their exosomes in the treatment of inflammatory bowel disease

1.
Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009
2.
Renocell Biotechnology Co., Ltd., Nanjing 211103, China

Funds: This study was supported by the National Natural Science Foundation of China (No. 82073928); the Nanjing Life and Health Science and Technology Program (No.202110006); the Haihe Laboratory of Cell Ecosystem Innovation Fund (22HHXBSS00005); and the Co-funded Programs in Nanjing, Jiangsu Province (SBK2023070039)

More Information

Received Date: November 29, 2023
Available Online: March 05, 2024

Graphical Abstract

Abstract

Abstract

Inflammatory bowel disease (IBD), whose pathogenesis remains elusive, is a group of autoimmune diseases characterized by chronic, progressive, and lifelong inflammation of the digestive tract. The pathogenesis of IBD remains elusive. Although a number of drugs have been developed to treat IBD, their effects are merely anti-inflammatory. In addition, current treatments for IBD are easily susceptible to resistance in clinical practice. Mesenchymal stem cells (MSCs) have been reported to have the ability to migrate to the site of inflammation, with potent immunoregulatory effects, and to rebalance the immune microenvironment and restore the integrity of the epithelial barrier with significant value of application, particularly for patients who are refractory to classic medicines. In this paper, we reviewed the clinical applications, mechanisms and engineerable properties of MSC products and their exosomes to provide some reference for the use of MSCs and their exosomes in the treatment of IBD.
- inflammatory bowel disease,
- mesenchymal stem cells,
- exosomes,
- engineering

FullText(HTML)

References (83)

References

[1]	Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody CA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease CA2 Study Group[J]. N Engl J Med, 1997, 337(15): 1029-1035. doi: 10.1056/NEJM199710093371502
[2]	Ward D, Nyboe Andersen N, Gørtz S, et al. Tumor necrosis factor inhibitors in inflammatory bowel disease and risk of immune mediated inflammatory diseases[J]. Clin Gastroenterol Hepatol, 2024, 22(1): 135-143. e8.
[3]	Beaugerie L, Rahier JF, Kirchgesner J. Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases[J]. Clin Gastroenterol Hepatol, 2020, 18(6): 1324-1335. e2.
[4]	Click B, Regueiro M. A practical guide to the safety and monitoring of new IBD therapies[J]. Inflamm Bowel Dis, 2019, 25(5): 831-842. doi: 10.1093/ibd/izy313
[5]	le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study[J]. Lancet, 2008, 371(9624): 1579-1586. doi: 10.1016/S0140-6736(08)60690-X
[6]	Álvaro-Gracia JM, Jover JA, García-Vicuña R, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial[J]. Ann Rheum Dis, 2017, 76(1): 196-202. doi: 10.1136/annrheumdis-2015-208918
[7]	Wu K, Liang J, Ran Z, et al. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018)[J]. Chin J Pract Intern Med(中国实用内科杂志), 2018, 38(9): 796-813.
[8]	Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review[J]. Clin Gastroenterol Hepatol, 2018, 16(3): 343-356. e3.
[9]	Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis[J]. Cochrane Database Syst Rev, 2006(2): CD000543.
[10]	Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomised, investigator-blind study[J]. Dig Liver Dis, 2003, 35(9): 619-627. doi: 10.1016/S1590-8658(03)00372-4
[11]	Cassinotti A, Corona A, Duca P, et al. Noninvasive monitoring after azathioprine withdrawal in patients with inflammatory bowel disease in deep remission[J]. Clin Gastroenterol Hepatol, 2021, 19(11): 2293-2301. e1.
[12]	Wylezinski LS, Gray JD, Polk JB, et al. Illuminating an invisible epidemic: a systemic review of the clinical and economic benefits of early diagnosis and treatment in inflammatory disease and related syndromes[J]. J Clin Med, 2019, 8(4): 493. doi: 10.3390/jcm8040493
[13]	Parigi TL, D’Amico F, Abreu MT, et al. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting[J]. Lancet Gastroenterol Hepatol, 2023, 8(9): 853-859. doi: 10.1016/S2468-1253(23)00154-1
[14]	Liu JZ, van Sommeren S, Huang HL, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations[J]. Nat Genet, 2015, 47(9): 979-986. doi: 10.1038/ng.3359
[15]	Ye ZQ, Qian L, Hu WH, et al. Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency[J]. Aliment Pharmacol Ther, 2022, 55(11): 1414-1422. doi: 10.1111/apt.16837
[16]	Moltzau Anderson J, Lipinski S, Sommer F, et al. NOD2 influences trajectories of intestinal microbiota recovery after antibiotic perturbation[J]. Cell Mol Gastroenterol Hepatol, 2020, 10(2): 365-389. doi: 10.1016/j.jcmgh.2020.03.008
[17]	Strigli A, Gopalakrishnan S, Zeissig Y, et al. Deficiency in X-linked inhibitor of apoptosis protein promotes susceptibility to microbial triggers of intestinal inflammation[J]. Sci Immunol, 2021, 6(65): eabf7473. doi: 10.1126/sciimmunol.abf7473
[18]	Baumgart DC, Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease[J]. N Engl J Med, 2021, 385(14): 1302-1315. doi: 10.1056/NEJMra1907607
[19]	Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoetic stem cell transplantation for refractory crohn disease: a randomized clinical trial[J]. JAMA, 2015, 314(23): 2524-2534. doi: 10.1001/jama.2015.16700
[20]	Lindsay JO, Allez M, Clark M, et al. Autologous stem-cell transplantation in treatment-refractory Crohn’s disease: an analysis of pooled data from the ASTIC trial[J]. Lancet Gastroenterol Hepatol, 2017, 2(6): 399-406. doi: 10.1016/S2468-1253(17)30056-0
[21]	Lightner AL, Dadgar N, Matyas C, et al. A phase IB/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis[J]. Colorectal Dis, 2022, 24(11): 1358-1370. doi: 10.1111/codi.16239
[22]	Grégoire C, Lechanteur C, Briquet A, et al. Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases[J]. Aliment Pharmacol Ther, 2017, 45(2): 205-221. doi: 10.1111/apt.13864
[23]	Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy[J]. Clin Gastroenterol Hepatol, 2014, 12(1): 64-71. doi: 10.1016/j.cgh.2013.06.021
[24]	Martin JC, Chang C, Boschetti G, et al. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy[J]. Cell, 2019, 178(6): 1493-1508. e20.
[25]	Friedrich M, Pohin M, Jackson MA, et al. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies[J]. Nat Med, 2021, 27(11): 1970-1981. doi: 10.1038/s41591-021-01520-5
[26]	West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease[J]. Nat Med, 2017, 23(5): 579-589. doi: 10.1038/nm.4307
[27]	Xu CC, Feng C, Huang PQ, et al. TNF-α and IFN-γ rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property[J]. Stem Cell Res Ther, 2022, 13(1): 491. doi: 10.1186/s13287-022-03178-3
[28]	Song WJ, Li Q, Ryu MO, et al. TSG-6 released from intraperitoneally injected canine adipose tissue-derived mesenchymal stem cells ameliorate inflammatory bowel disease by inducing M2 macrophage switch in mice[J]. Stem Cell Res Ther, 2018, 9(1): 91. doi: 10.1186/s13287-018-0841-1
[29]	Qi LL, Wu J, Zhu S, et al. Mesenchymal stem cells alleviate inflammatory bowel disease via Tr1 cells[J]. Stem Cell Rev Rep, 2022, 18(7): 2444-2457. doi: 10.1007/s12015-022-10353-9
[30]	Akiyama K, Chen C, Wang DD, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/ FAS-mediated T cell apoptosis[J]. Cell Stem Cell, 2012, 10(5): 544-555. doi: 10.1016/j.stem.2012.03.007
[31]	Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota[J]. Gastroenterology, 2002, 122(4): 875-880. doi: 10.1053/gast.2002.32362
[32]	Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab[J]. Clin Gastroenterol Hepatol, 2013, 11(8): 975-981. e1-4.
[33]	Reenaers C, Gillard RP, Coimbra C, et al. Clinical and MRI evolution after local injection of bone marrow-derived mesenchymal stem cells in perianal fistulae in Crohn’s disease: results from a prospective monocentric study[J]. J Crohns Colitis, 2023, 17(5): 728-737. doi: 10.1093/ecco-jcc/jjac192
[34]	Panés J, García-Olmo D, van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial[J]. Lancet, 2016, 388(10051): 1281-1290. doi: 10.1016/S0140-6736(16)31203-X
[35]	Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease[J]. Gut, 2011, 60(6): 788-798. doi: 10.1136/gut.2010.214841
[36]	Cho YB, Park KJ, Yoon SN, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula[J]. Stem Cells Transl Med, 2015, 4(5): 532-537. doi: 10.5966/sctm.2014-0199
[37]	Bataille F, Klebl F, Rümmele P, et al. Morphological characterisation of Crohn’s disease fistulae[J]. Gut, 2004, 53(9): 1314-1321. doi: 10.1136/gut.2003.038208
[38]	Alexander M, Ang QY, Nayak RR, et al. Human Gut bacterial metabolism drives Th17 activation and colitis[J]. Cell Host Microbe, 2022, 30(1): 17-30. e9.
[39]	Barnhoorn MC, van der Meulen-de Jong AE, Schrama ECLM, et al. Cytokine mixtures mimicking the local milieu in patients with inflammatory bowel disease impact phenotype and function of mesenchymal stromal cells[J]. Stem Cells Transl Med, 2022, 11(9): 932-945. doi: 10.1093/stcltm/szac054
[40]	Li Y, Altemus J, Lightner AL. Mesenchymal stem cells and acellular products attenuate murine induced colitis[J]. Stem Cell Res Ther, 2020, 11(1): 515. doi: 10.1186/s13287-020-02025-7
[41]	Wang GY, Joel MDM, Yuan JT, et al. Human umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease by inhibiting ERK phosphorylation in neutrophils[J]. Inflammopharmacology, 2020, 28(2): 603-616. doi: 10.1007/s10787-019-00683-5
[42]	Kim HS, Shin TH, Lee BC, et al. Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2[J]. Gastroenterology, 2013, 145(6): 1392-1403. e1-8.
[43]	Mei HF, Sun LX, Jiang ZZ, et al. Sphingosine 1-phosphate signaling pathway: a novel target for regulation of epithelial and endothelial barrier function[J]. J China Pharm Univ (中国药科大学学报), 2016, 47(6): 654-660.
[44]	Yousefi-Ahmadipour A, Rashidian A, Mirzaei MR, et al. Combination therapy of mesenchymal stromal cells and sulfasalazine attenuates trinitrobenzene sulfonic acid induced colitis in the rat: the S1P pathway[J]. J Cell Physiol, 2019, 234(7): 11078-11091. doi: 10.1002/jcp.27944
[45]	Tian J, Zhu QG, Zhang YD, et al. Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate experimental colitis via modulating Th1/Th17 and Treg cell responses[J]. Front Immunol, 2020, 11: 598322. doi: 10.3389/fimmu.2020.598322
[46]	Webb TL, Webb CB. Comparing adipose-derived mesenchymal stem cells with prednisolone for the treatment of feline inflammatory bowel disease[J]. J Feline Med Surg, 2022, 24(8): e244-e250. doi: 10.1177/1098612X221104053
[47]	Freitas Alves VBF, de Sousa BC, Fonseca MTC, et al. A single administration of human adipose tissue-derived mesenchymal stromal cells (MSC) induces durable and sustained long-term regulation of inflammatory response in experimental colitis[J]. Clin Exp Immunol, 2019, 196(2): 139-154. doi: 10.1111/cei.13262
[48]	Fan HY, Zhao GF, Liu L, et al. Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis[J]. Cell Mol Immunol, 2012, 9(6): 473-481. doi: 10.1038/cmi.2012.40
[49]	Duijvestein M, Wildenberg ME, Welling MM, et al. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis[J]. Stem Cells, 2011, 29(10): 1549-1558. doi: 10.1002/stem.698
[50]	Takenaka K, Ohtsuka K, Fujii T, et al. Deep neural network accurately predicts prognosis of ulcerative colitis using endoscopic images[J]. Gastroenterology, 2021, 160(6): 2175-2177. e3.
[51]	Fernandes SR, Serrazina J, Botto IA, et al. Transmural remission improves clinical outcomes up to 5years in Crohn’s disease[J]. United European Gastroenterol J, 2023, 11(1): 51-59. doi: 10.1002/ueg2.12356
[52]	Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease[J]. Inflamm Bowel Dis, 2009, 15(9): 1295-1301. doi: 10.1002/ibd.20927
[53]	Danese S, Vermeire S, D’Haens G, et al. Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(4): 294-306. doi: 10.1016/S2468-1253(21)00474-X
[54]	Manieri NA, Mack MR, Himmelrich MD, et al. Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis[J]. J Clin Invest, 2015, 125(9): 3606-3618. doi: 10.1172/JCI81423
[55]	Yang HS, Feng R, Fu QL, et al. Human induced pluripotent stem cell-derived mesenchymal stem cells promote healing via TNF-α-stimulated gene-6 in inflammatory bowel disease models[J]. Cell Death Dis, 2019, 10(10): 718. doi: 10.1038/s41419-019-1957-7
[56]	Xu J, Wang XF, Chen JY, et al. Embryonic stem cell-derived mesenchymal stem cells promote colon epithelial integrity and regeneration by elevating circulating IGF-1 in colitis mice[J]. Theranostics, 2020, 10(26): 12204-12222. doi: 10.7150/thno.47683
[57]	Wang DD, Xue H, Tan JF, et al. Bone marrow mesenchymal stem cells-derived exosomes containing miR-539-5p inhibit pyroptosis through NLRP3/caspase-1 signalling to alleviate inflammatory bowel disease[J]. Inflamm Res, 2022, 71(7/8): 833-846.
[58]	Liang XN, Li CY, Song J, et al. HucMSC-exo promote mucosal healing in experimental colitis by accelerating intestinal stem cells and epithelium regeneration via Wnt signaling pathway[J]. Int J Nanomedicine, 2023, 18: 2799-2818. doi: 10.2147/IJN.S402179
[59]	Venkataramana S, Lourenssen S, Miller KG, et al. Early inflammatory damage to intestinal neurons occurs via inducible nitric oxide synthase[J]. Neurobiol Dis, 2015, 75: 40-52. doi: 10.1016/j.nbd.2014.12.014
[60]	Gulbransen BD, Bashashati M, Hirota SA, et al. Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis[J]. Nat Med, 2012, 18(4): 600-604. doi: 10.1038/nm.2679
[61]	Dong Y, Fischer R, Naudé PJ, et al. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration[J]. Proc Natl Acad Sci U S A, 2016, 113(43): 12304-12309. doi: 10.1073/pnas.1605195113
[62]	Robinson AM, Rahman AA, Miller S, et al. The neuroprotective effects of human bone marrow mesenchymal stem cells are dose-dependent in TNBS colitis[J]. Stem Cell Res Ther, 2017, 8(1): 87. doi: 10.1186/s13287-017-0540-3
[63]	Louis E, Collard A, Oger AF, et al. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease[J]. Gut, 2001, 49(6): 777-782. doi: 10.1136/gut.49.6.777
[64]	de Bruyn JR, Meijer SL, Wildenberg ME, et al. Development of fibrosis in acute and longstanding ulcerative colitis[J]. J Crohns Colitis, 2015, 9(11): 966-972. doi: 10.1093/ecco-jcc/jjv133
[65]	D’Alessio S, Ungaro F, Noviello D, et al. Revisiting fibrosis in inflammatory bowel disease: the Gut thickens[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(3): 169-184. doi: 10.1038/s41575-021-00543-0
[66]	Yang J, Zhou CZ, Zhu R, et al. MiR-200b-containing microvesicles attenuate experimental colitis associated intestinal fibrosis by inhibiting epithelial-mesenchymal transition[J]. J Gastroenterol Hepatol, 2017, 32(12): 1966-1974. doi: 10.1111/jgh.13797
[67]	Ye YX, Zhang XM, Su DS, et al. Therapeutic efficacy of human adipose mesenchymal stem cells in Crohn’s colon fibrosis is improved by IFN-γ and kynurenic acid priming through indoleamine 2, 3-dioxygenase-1 signaling[J]. Stem Cell Res Ther, 2022, 13(1): 465. doi: 10.1186/s13287-022-03157-8
[68]	Zheng XB, He XW, Zhang LJ, et al. Bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice[J]. Gastroenterol Rep, 2019, 7(2): 127-138. doi: 10.1093/gastro/goy017
[69]	Fu Y, Ni JJ, Chen JH, et al. Dual-functionalized MSCs that express CX3CR1 and IL-25 exhibit enhanced therapeutic effects on inflammatory bowel disease[J]. Mol Ther, 2020, 28(4): 1214-1228. doi: 10.1016/j.ymthe.2020.01.020
[70]	Li QJ, Lian YF, Deng YW, et al. mRNA-engineered mesenchymal stromal cells expressing CXCR2 enhances cell migration and improves recovery in IBD[J]. Mol Ther Nucleic Acids, 2021, 26: 222-236. doi: 10.1016/j.omtn.2021.07.009
[71]	Li X, Wang Q, Ding L, et al. Intercellular adhesion molecule-1 enhances the therapeutic effects of MSCs in a dextran sulfate sodium-induced colitis models by promoting MSCs homing to murine colons and spleens[J]. Stem Cell Res Ther, 2019, 10(1): 267. doi: 10.1186/s13287-019-1384-9
[72]	Ye TH, Liu X, Zhong XH, et al. Nongenetic surface engineering of mesenchymal stromal cells with polyvalent antibodies to enhance targeting efficiency[J]. Nat Commun, 2023, 14(1): 5806. doi: 10.1038/s41467-023-41609-8
[73]	Li L, Yao ZC, Parian A, et al. A nanofiber-hydrogel composite improves tissue repair in a rat model of Crohn’s disease perianal fistulas[J]. Sci Adv, 2023, 9(1): eade1067. doi: 10.1126/sciadv.ade1067
[74]	Wei M, Dang Y, Pu Z, et al. Pharmacokinetics and druggability evaluation of mesenchymal stem cells[J]. Drug Eval Res (药物评价研究), 2023, 46(7): 1587-1594.
[75]	Wei N, Wang G, Zhang J. Advances in research on visualization of living cell drugs in vivo[J]. J China Pharm Univ(中国药科大学学报), 2022, 53(2): 156-163. doi: 10.11665/j.issn.1000-5048.20220204
[76]	Zhang Q, Luo X, Bao Y, et al. Research progress in biomimetic nano formulations of biofilms[J]. J China Pharm Univ(中国药科大学学报), 2023, 54(5): 544-552.
[77]	Wu H, Fan H, Shou ZX, et al. Extracellular vesicles containing miR-146a attenuate experimental colitis by targeting TRAF6 and IRAK1[J]. Int Immunopharmacol, 2019, 68: 204-212. doi: 10.1016/j.intimp.2018.12.043
[78]	Gan JJ, Sun LY, Chen GP, et al. Mesenchymal stem cell exosomes encapsulated oral microcapsules for acute colitis treatment[J]. Adv Healthc Mater, 2022, 11(17): e2201105. doi: 10.1002/adhm.202201105
[79]	Deng C, Hu YW, Conceição M, et al. Oral delivery of layer-by-layer coated exosomes for colitis therapy[J]. J Control Release, 2023, 354: 635-650. doi: 10.1016/j.jconrel.2023.01.017
[80]	Haneef K, Salim A, Hashim Z, et al. Chemical hypoxic preconditioning improves survival and proliferation of mesenchymal stem cells[J]. Appl Biochem Biotechnol, 2023.
[81]	Jin LH, Lu N, Zhang WX, et al. Altered properties of human adipose-derived mesenchymal stromal cell during continuous in vitro cultivation[J]. Cytotechnology, 2021, 73(4): 657-667. doi: 10.1007/s10616-021-00486-z
[82]	Haraszti RA, Miller R, Stoppato M, et al. Exosomes produced from 3D cultures of MSCs by tangential flow filtration show higher yield and improved activity[J]. Mol Ther, 2018, 26(12): 2838-2847. doi: 10.1016/j.ymthe.2018.09.015
[83]	Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7(1): 1535750. doi: 10.1080/20013078.2018.1535750

[1]	WANG Xuefang, ZHAO Yang, LIU Zhuqing, GUO Le, ZHONG Feiliang, LUO Xuegang. Genetic engineering and molecular modification of recombinant fully humanized single-domain antibody against Helicobacter pylori UreB[J]. Journal of China Pharmaceutical University, 2024, 55(5): 666-672. DOI: 10.11665/j.issn.1000-5048.2023122903
[2]	SUN Yimei, MAO Shihui, LI Lin, JIANG Weifeng, CHU Lisheng. Bone marrow mesenchymal stem cell-derived exosomes promote microglia/macrophage M2 polarization in acute cerebral ischemia rats and inhibit inflammatory response[J]. Journal of China Pharmaceutical University, 2023, 54(5): 599-606. DOI: 10.11665/j.issn.1000-5048.2023041703
[3]	ZHANG Heng, CHEN Qianqian, GUI Yanping, HUANG Min, GUO Yabing, ZHAO Li. Mechanism of M2 macrophage-derived exosomes in promoting the migration of glioblastoma via transferring miR-1260b[J]. Journal of China Pharmaceutical University, 2023, 54(1): 95-106. DOI: 10.11665/j.issn.1000-5048.2023020901
[4]	ZHAO Yuekui, TANG Shanshan, ZHANG Yanfeng, ZONG Li, JIN Liang. Engineered mesenchymal stem cells as targeting therapeutic carriers in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(2): 134-139. DOI: 10.11665/j.issn.1000-5048.20160202
[5]	WANG Shu, ZHANG Zhenhai, GU Dongfei, ZHOU Jianping, LYV Huixia. Advances of exosomes as a new drug delivery system[J]. Journal of China Pharmaceutical University, 2014, 45(2): 247-252. DOI: 10.11665/j.issn.1000-5048.20140221
[6]	LI Hui, WEN Shuping, HONG Wenrong. Construction of carbamoyltobramcin-producing engineering S.tenebrarius by disruption of aprK gene[J]. Journal of China Pharmaceutical University, 2013, 44(4): 368-373. DOI: 10.11665/j.issn.1000-5048.20130416
[7]	Study on the Fermentation Characterizatics of Micromonospora Inyoensis Engineering Strain S96[J]. Journal of China Pharmaceutical University, 2003, (5): 83-86.
[8]	BZHONG Wen-Rong, SHI Xian-Ai, LIN Juan, CHENG Ji. Studied on the Culture Characteristics of Micromonospora Inyoensis Engineering Strains S96[J]. Journal of China Pharmaceutical University, 2003, (2).
[9]	Fermentation Conditions for High Level Expression of Novel Human Calcitonin Analogue Gene in Engineering Strain[J]. Journal of China Pharmaceutical University, 2000, (2): 74-77.
[10]	Primary Studies on the Immobilization of an Engineering E. coli Strain with High Activity of Aromatic Amino Acid Transaminase[J]. Journal of China Pharmaceutical University, 1994, (5): 316-318.

Cited By

Cited by

Periodical cited type(1)

袁潇，梁松林，谢亚楠，管冬梅，樊龙雨，殷晓轩. 不同来源间充质干细胞治疗炎症性肠病. 中国组织工程研究. 2025(31): 6811-6820 .

Other cited types(2)

Get Citation

PDF

XML

Article views (360) PDF downloads (32) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Research progress on mesenchymal stem cell products and their exosomes in the treatment of inflammatory bowel disease